aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE) announced that it will release its fourth-quarter and full-year 2020 financial results on March 23, 2021, after market close. The management will hold a conference call and webcast at 5:00 PM EDT / 2:00 PM PDT to discuss these results and provide a corporate update. The company focuses on developing innovative medicines using novel biological pathways, particularly through its clinical-stage candidate ATYR1923, aimed at treating inflammatory lung diseases.

Positive

• Scheduled financial results announcement for Q4 and FY 2020 may reflect strong performance.
• Upcoming corporate update suggests proactive communication strategy.
• Focus on clinical-stage candidate ATYR1923 indicates potential growth in inflammatory lung disease market.

Negative

• None.

Management to host conference call and webcast on March 23rd at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update after the market close on Tuesday, March 23, 2021. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Tuesday, March 23rd @ 5:00 p.m. EDT / 2:00 p.m. PDT
Domestic: 844-358-9116
International: 209-905-5951
Conference ID: 3291668
Webcast: http://investors.atyrpharma.com/events-and-webcasts

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

FAQ

When will aTyr Pharma announce its fourth-quarter and full-year 2020 financial results?

aTyr Pharma will announce its financial results on March 23, 2021.

What is the significance of ATYR1923 for aTyr Pharma?

ATYR1923 is a clinical-stage product candidate aimed at treating inflammatory lung diseases.

How can I access the conference call and webcast for aTyr Pharma?

You can access the conference call and webcast on March 23, 2021, through their official investor relations page.

What time will the aTyr Pharma conference call take place?

The conference call will take place at 5:00 PM EDT / 2:00 PM PDT on March 23, 2021.